FeesSafety
Pluang+

Darovasertib plus crizotinib shows promise in treating metastatic and primary uveal melanoma, improving survival and eye preservation.

Company Fundamentals
19 Oct 2026, 13:00 WIB
PRNewsWire
View Source
Bullish
Darovasertib plus crizotinib shows promise in treating metastatic and primary uveal melanoma, improving survival and eye preservation.

IDEAYA Biosciences presented updated data at ESMO 2026 showing that darovasertib combined with crizotinib offers meaningful clinical benefits for metastatic uveal melanoma patients regardless of HLA-A*02:01 status. The OptimUM-01 and OptimUM-02 trials demonstrated improved progression-free survival and overall survival compared to historical benchmarks and investigator's choice therapies. Additionally, the OptimUM-09 trial showed that neoadjuvant darovasertib significantly shrinks tumors in primary uveal melanoma, increasing eye preservation rates and reducing radiation exposure. These results support darovasertib as a potential new standard of care across the uveal melanoma treatment journey, with a new drug application expected in late 2026.

Darovasertib's potential as a new therapy for uveal melanoma is highlighted alongside Pluang's health sector market data. For readers following health stocks, here is Pluang's market snapshot as of Oct 19, 2026 15:51 WIB: out of 150 priced US health stocks, 69 rose and 42 fell. Notable movers include Sana Biotechnology Inc (SANA) at USD 2.33 with a +2.64% change and a typical hold time of 24 days, Moderna, Inc. (MRNA) at USD 212.36 down -2.59% with a 59-day hold, and Cytokinetics Inc (CYTK) at USD 63.50 up +2.50% with a 20-day hold.

More News

800V DC circuit breaker market for data centers to hit $2.11B by 2036 with 41% CAGR driven by AI infrastructure growth

800V DC circuit breaker market for data centers to hit $2.11B by 2036 with 41% CAGR driven by AI infrastructure growth

The global 800V DC circuit breaker market for data centers is projected to grow from $68 million in 2026 to $2.11 billion by 2036, driven by rising rack power needs and AI data center expansion. Key technologies include mechanical, solid-state, and h...

Market News
Bullish
50 minutes ago
Global aerospace market to nearly double to $846B by 2035 amid record backlogs and supply chain challenges

Global aerospace market to nearly double to $846B by 2035 amid record backlogs and supply chain challenges

The global aerospace market is projected to grow from $434.17 billion in 2026 to $846.30 billion by 2035, driven by record order backlogs at Boeing, Airbus, GE Aerospace, and RTX. Demand is strong due to rising air travel, fleet replacements, and def...

Bullish
50 minutes ago
Etsy edges out Dick's Sporting Goods with higher profitability and lower valuation despite slower revenue growth.

Etsy edges out Dick's Sporting Goods with higher profitability and lower valuation despite slower revenue growth.

Dick's Sporting Goods and Etsy represent two distinct retail models: a traditional omnichannel retailer and a high-margin digital marketplace. Dick's shows strong revenue growth of 22% annually but lower profitability with a 6.4% operating margin, wh...

Market News
Bullish
55 minutes ago
Anthropic raises $81.3B in record IPO priced at $83 per share, valued at $1.5 trillion.

Anthropic raises $81.3B in record IPO priced at $83 per share, valued at $1.5 trillion.

Anthropic, the AI company behind Claude models, launched its IPO on Nasdaq at $83 per share, raising $81.3 billion and valuing the company at about $1.5 trillion. This marks the largest IPO ever, surpassing SpaceX's record. The company sold 980 milli...

Market News
Neutral
1 hour ago
Rocket Lab delays Neutron rocket launch to 2027 amid technical setbacks and stock pressure.

Rocket Lab delays Neutron rocket launch to 2027 amid technical setbacks and stock pressure.

Rocket Lab has postponed the debut of its medium-lift Neutron rocket to 2027 due to technical issues during testing, including a tank rupture and air pockets in composite materials. Neutron aims to carry much larger payloads than Rocket Lab's current...

Company Fundamentals
Bearish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App